Low Public Signal

TMB-high

breast cancer · Immune Checkpoint Inhibitor

TMB-high is flagged as low public signal because public trials show inclusion required evidence in 1 contexts. FDA CDx context should be reviewed manually.

Role evidence

Usage summary

Strongest role: Inclusion Required

Inclusion-required count: 1

Treatment-assignment count: 0

Stratification count: 0

Threshold snippets

Fragmentation view

Threshold count: 2

Common snippets: MSI-H | MSI-H

Threshold label: Low

FDA CDx context

Mapping summary

CDx label: Fda Cdx Context Not Found

CDx maturity score: 1/5

Confidence: High

Patent-density signal

Diagnostic appendix

Signal count: 0

Recent signals: 0

Density label: Low

Source links

Evidence paths

https://clinicaltrials.gov/study/NCT04787042